Technical Analysis for CYYNF - Cynata Therapeutics Ltd Ordinar

Grade Last Price % Change Price Change
grade C 0.72 -13.25% -0.1100
CYYNF closed down 13.25 percent on Wednesday, December 4, 2019, on 69 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Down
See historical CYYNF trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Gapped Down Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 50 DMA Bearish -13.25%
MACD Bearish Signal Line Cross Bearish -13.25%
Narrow Range Bar Range Contraction -13.25%

Older signals for CYYNF ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand name for human therapeutic use in Australia. Its lead therapeutic product candidate is CYP-001, which is in Phase I clinical trial for the treatment of graft versus host disease. The company also develops products for the treatment of heart attack, asthma, acute respiratory distress syndrome, diabetic wounds, coronary artery disease, brain cancer, and critical limb ischaemia, which are in preclinical model. The company has a partnership with Monash University, Critical Care Research Group, University of Sydney, Department of Neurosurgery at Brigham and Women's Hospital - Harvard Medical School, the Cooperative Research Centre for Cell Therapy Manufacturing, University of New South Wales, and the Royal College of Surgeons Ireland to develop stem cell therapies. It also has a strategic partnership with Fujifilm Corporation of Japan for the development and research of Cymerus technology. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Carlton, Australia.
Biotechnology Branches Of Biology Life Sciences Biology Stem Cells Cell Therapy Cell Biology Asthma Neurosurgery Coronary Artery Disease Heart Attack Mesoblast Host Disease Brain Cancer Harvard Medical School Stem Cell Therapies Treatment Of Graft Versus Host Disease University Of New South Wales

Is CYYNF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 1.25
52 Week Low 0.34
Average Volume 3,648
200-Day Moving Average 0.0000
50-Day Moving Average 0.8420
20-Day Moving Average 0.9273
10-Day Moving Average 0.9650
Average True Range 0.0977
ADX 13.5
+DI 42.5059
-DI 57.1941
Chandelier Exit (Long, 3 ATRs ) 0.9569
Chandelier Exit (Short, 3 ATRs ) 1.0131
Upper Bollinger Band 1.2196
Lower Bollinger Band 0.6350
Percent B (%b) 0.15
BandWidth 63.0432
MACD Line 0.0182
MACD Signal Line 0.0448
MACD Histogram -0.0265
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.7200
Resistance 3 (R3) 0.7200 0.7200 0.7200
Resistance 2 (R2) 0.7200 0.7200 0.7200 0.7200
Resistance 1 (R1) 0.7200 0.7200 0.7200 0.7200 0.7200
Pivot Point 0.7200 0.7200 0.7200 0.7200 0.7200
Support 1 (S1) 0.7200 0.7200 0.7200 0.7200 0.7200
Support 2 (S2) 0.7200 0.7200 0.7200 0.7200
Support 3 (S3) 0.7200 0.7200 0.7200
Support 4 (S4) 0.7200